HK1209133A1 - 用於降低抗體驟集物水平的方法以及由此制得的抗體 - Google Patents

用於降低抗體驟集物水平的方法以及由此制得的抗體

Info

Publication number
HK1209133A1
HK1209133A1 HK15109727.4A HK15109727A HK1209133A1 HK 1209133 A1 HK1209133 A1 HK 1209133A1 HK 15109727 A HK15109727 A HK 15109727A HK 1209133 A1 HK1209133 A1 HK 1209133A1
Authority
HK
Hong Kong
Prior art keywords
antibodies produced
aggregate levels
reducing antibody
antibody aggregate
reducing
Prior art date
Application number
HK15109727.4A
Other languages
English (en)
Inventor
Justyna Kucia
Marcel Kuiper
Richard Tran
David Gruber
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of HK1209133A1 publication Critical patent/HK1209133A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK15109727.4A 2012-02-03 2015-10-06 用於降低抗體驟集物水平的方法以及由此制得的抗體 HK1209133A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261594671P 2012-02-03 2012-02-03
PCT/EP2013/052078 WO2013113898A1 (en) 2012-02-03 2013-02-01 Process for reducing antibody aggregate levels and antibodies produced thereby

Publications (1)

Publication Number Publication Date
HK1209133A1 true HK1209133A1 (zh) 2016-03-24

Family

ID=47678781

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109727.4A HK1209133A1 (zh) 2012-02-03 2015-10-06 用於降低抗體驟集物水平的方法以及由此制得的抗體

Country Status (7)

Country Link
US (1) US20150005475A1 (zh)
EP (1) EP2855522A1 (zh)
JP (1) JP2015510397A (zh)
AU (1) AU2013214172A1 (zh)
CA (1) CA2863564A1 (zh)
HK (1) HK1209133A1 (zh)
WO (1) WO2013113898A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2895226T3 (es) 2009-10-16 2022-02-18 Mereo Biopharma 5 Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos
BR112014007035B1 (pt) 2011-09-23 2021-05-04 Oncomed Pharmaceuticals, Inc anticorpos biespecíficos que se ligam a vegf/dll4, composição farmacêutica e célula procariótica, fúngica ou de levedura que compreende os mesmos, moléculas de polinucleotídeo, vetor, usos terapêuticos e método para a produção de um anticorpo
DK3212233T3 (da) 2014-10-31 2020-07-27 Oncomed Pharm Inc Kombinationsterapi til behandling af sygdom
AU2016326609B2 (en) 2015-09-23 2023-03-09 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
US10310687B2 (en) * 2016-12-14 2019-06-04 Cypress Semiconductor Corporation Multi-phase self-capacitance scanning of sensors arrays

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO2010032060A1 (en) * 2008-09-19 2010-03-25 Medimmune Llc Antibodies directed to dll4 and uses thereof

Also Published As

Publication number Publication date
EP2855522A1 (en) 2015-04-08
CA2863564A1 (en) 2013-08-08
WO2013113898A1 (en) 2013-08-08
US20150005475A1 (en) 2015-01-01
AU2013214172A1 (en) 2014-08-14
JP2015510397A (ja) 2015-04-09

Similar Documents

Publication Publication Date Title
HUS2100034I1 (hu) ANGPTL3-ellenes antitestek és alkalmazásaik
IL288203A (en) Meditops and Meditop binding antibodies and their use
HK1256304A1 (zh) 用於生成單克隆抗體的方法和試劑
HK1210620A1 (zh) 多重特異性單克隆抗體
ZA201400768B (en) Interleukin-31 monoclonal antibody
IL232399A0 (en) Anti-2fgfr antibodies and their use
EP2742067A4 (en) MONOCLONAL FZD10 ANTIBODIES AND METHOD FOR THEIR USE
EP2746394A4 (en) ANTIBODY AND COMPOSITION CONTAINING THE SAME
HK1199842A1 (zh) 抗涎免凝集素- 抗體及其用途
EP2861623A4 (en) NEW SPECIFIC CLEC14A ANTIBODY AND USES THEREOF
EP2915819A4 (en) METHOD FOR PRODUCING ANTIBODIES AND ANTIBODY COMPOSITION
SG11201400405TA (en) Caninised antibodies and method for the production of same
HK1209133A1 (zh) 用於降低抗體驟集物水平的方法以及由此制得的抗體
HRP20150468T1 (hr) Protutijela koja se vežu na tgf-alfa i epiregulin